Estradiol is not made from horse urine. This is one of the most persistent mix-ups in hormone therapy, and it stems from confusing two very different medications. The product actually derived from the urine of pregnant mares is conjugated equine estrogens, best known by the brand name Premarin. Estradiol, by contrast, is a lab-synthesized molecule identical to the estrogen your own body produces, typically manufactured from plant-derived starting materials like soy or wild yam. The two drugs share a broad category but differ in their chemistry, their source, and the way they behave in your body.
Where the Confusion Comes From
Both estradiol and conjugated equine estrogens (CEE) are prescribed for the same purpose: relieving menopausal symptoms like hot flashes, night sweats, and vaginal dryness. They both fall under the umbrella of “estrogen therapy,” and for decades CEE was the dominant prescription in the United States. Premarin was introduced in the 1940s and became one of the most widely prescribed drugs in the country by the 1990s. Because it was so synonymous with hormone therapy, many people came to assume that all prescription estrogen comes from horses.
The rise of bioidentical hormone therapy in public conversation added another layer of confusion. Marketing materials from compounding pharmacies sometimes position their products against “horse estrogen” without clearly explaining that FDA-approved estradiol patches, gels, and pills are also not derived from horses. The implication, whether intentional or not, is that anything prescribed by a conventional doctor might be equine-sourced. That framing is misleading.
What Premarin Actually Contains
Premarin is extracted from the urine of pregnant mares, hence the name (pregnant mares’ urine). But it is not simply estradiol from a horse. Pregnant mares produce a distinctive set of estrogens that human bodies do not make in meaningful quantities. The most prominent of these are equilin and equilenin, which belong to a class sometimes called ring B unsaturated estrogens. Research on the pregnant mare’s metabolism has shown that these estrogens follow a biosynthetic pathway distinct from the one that produces estrone and estradiol, and that pathway appears to be independent of cholesterol as a precursor.
When researchers traced how equilin is processed in a pregnant mare, they found that roughly 75% of the radioactive material ended up as sulfate-bound forms of equilin and its metabolites, including dihydroequilin and dihydroequilenin. Classical estrogens like estrone and estradiol were also isolated from the urine, but they carried no radioactivity, meaning they were not breakdown products of equilin. The B ring unsaturated estrogens and the classical estrogens travel separate metabolic tracks in the horse.
So when you take Premarin, you are ingesting a complex mixture that includes at least ten different estrogen compounds, most of which are unique to horses. This is fundamentally different from taking a pill or wearing a patch that delivers 17β-estradiol alone.
How Estradiol Is Actually Made
The 17β-estradiol used in FDA-approved medications like Estrace, Vivelle-Dot, and Climara is produced through chemical synthesis. The usual starting material is diosgenin, a compound extracted from soybeans or the tubers of wild yam plants. Through a series of chemical reactions, diosgenin is converted into a molecule that is structurally identical, atom for atom, to the estradiol produced by human ovaries. This process has been refined over many decades and is standard pharmaceutical manufacturing.
The history of estrogen isolation helps explain why plant-derived synthesis eventually won out. In the 1920s, researchers first crystallized estrone from biological sources, and the earliest purification work relied on enormous quantities of animal tissue and human pregnancy urine. Edgar Allen’s early studies used follicular fluid from sow ovaries, and progress accelerated when Selmar Ascheim and Bernard Zondek showed that pregnant women’s urine contained large amounts of estrogenic activity. Edward Doisy crystallized estrone in 1929, presenting the finding at an international congress, and estradiol was isolated shortly afterward. Once the molecular structures were known, chemists could build them from scratch using cheaper and more scalable plant precursors.
How Equine Estrogens Behave Differently in Your Body
The chemical differences between equine estrogens and human estradiol are not just academic. They translate into measurably different biological activity. Research on how these molecules interact with estrogen receptors has revealed a telling pattern. Human cells have two main types of estrogen receptor, ERα and ERβ, and the equine estrogens engage them in a noticeably different ratio than 17β-estradiol does.
Most of the ring B unsaturated estrogens found in Premarin bind to both receptors with affinities roughly two to eight times lower than estradiol for each receptor. But several of them show a preference for ERβ, binding it with two to four times greater affinity than ERα. When researchers measured the actual functional activity of these estrogens in cells containing both receptor types, equilenin turned out to be the most active compound through ERβ. Some equine estrogens, including dihydroequilin and dihydroequilenin, showed enhanced activity when both receptor subtypes were present, reaching levels well above what estradiol achieved through that same pathway. Estradiol, in contrast, was far more potent through ERα than any other estrogen tested.
This matters because ERα and ERβ are distributed differently across tissues. The breast, uterus, and liver are rich in ERα, while bone, the cardiovascular system, and certain brain regions have substantial ERβ expression. A drug that preferentially activates one receptor subtype over another can, in theory, produce a different profile of effects across the body. This is part of why researchers have observed that CEE and estradiol do not always produce identical clinical outcomes, even though both relieve menopausal symptoms effectively.
Do the Safety Profiles Actually Differ?
One of the most clinically relevant distinctions between CEE and estradiol involves blood clot risk. A study comparing real-world outcomes in women taking oral estradiol with micronized progesterone versus those taking oral CEE with medroxyprogesterone acetate found that venous thromboembolism occurred at a rate of about 37 per 10,000 women-years in the estradiol group compared with about 53 per 10,000 women-years in the CEE group. That translates to roughly a 30% lower incidence in the estradiol users.
This difference has biological plausibility. CEE contains multiple estrogen compounds that are metabolized through the liver in ways that differ from estradiol, and the liver is where clotting factor production happens. Oral estradiol also passes through the liver and does affect hepatic proteins. Studies in postmenopausal women have shown that oral estradiol raises sex hormone-binding globulin concentrations substantially, and similar effects on thyroid-binding globulin and insulin-like growth factor have been documented. But transdermal estradiol largely bypasses the liver on its first pass through the body, which is why patches and gels tend to have a smaller impact on clotting factors and liver-produced proteins than any oral estrogen does.
The practical takeaway for women considering hormone therapy is that the route of delivery (oral versus through the skin) matters alongside the type of estrogen. For women with elevated clot risk, transdermal estradiol is generally considered the safer option compared to any oral estrogen, whether that oral estrogen is CEE or estradiol.
What “Bioidentical” Actually Means
The term “bioidentical” has become a flashpoint in menopause medicine, and it contributes to the horse-urine confusion in a roundabout way. Bioidentical simply means the hormone molecule is chemically identical to what the human body produces. By this definition, the 17β-estradiol in FDA-approved patches and pills is bioidentical. So is the micronized progesterone in products like Prometrium. These are regulated, standardized medications with well-studied safety profiles.
The problem is that compounding pharmacies have adopted “bioidentical” as a marketing term to suggest their custom-mixed preparations are more natural and therefore safer than conventional prescriptions. The American College of Obstetricians and Gynecologists has warned that this framing implies safety and effectiveness advantages that are not supported by evidence, and that compounded bioidentical hormone therapy should not be routinely prescribed when FDA-approved formulations are available. A systematic review of randomized trials of compounded bioidentical hormones found that while the trends in absorption and effect were broadly consistent with data from FDA-approved products, the compounded versions lack the same quality controls, batch-to-batch consistency, and regulatory oversight.
This creates a confusing landscape for consumers. A woman who hears “bioidentical” pitched against “horse urine” might reasonably conclude that her choices are either a custom compounded cream or Premarin, when in fact FDA-approved estradiol products are bioidentical, widely available, and thoroughly tested. The dichotomy between “natural bioidentical” and “horse estrogen” is a false one that obscures the real range of options.
Oral Versus Transdermal Delivery
Beyond the question of which estrogen molecule you are taking, how it gets into your bloodstream changes its effects in important ways. Oral estradiol, like oral CEE, is swallowed and absorbed through the gut, then passes through the liver before reaching the rest of the body. This first-pass liver metabolism amplifies certain effects. In postmenopausal women, oral estradiol increased sex hormone-binding globulin by 67% to 171%, depending on the study population. In menopausal women with hypothyroidism, oral estradiol significantly raised both thyroid-binding globulin and SHBG while lowering insulin-like growth factor-1. Transdermal estradiol did not produce these hepatic changes.
In younger patients, the same principle holds. A randomized trial in girls with Turner syndrome found that oral estradiol produced significantly higher levels of estrone, estrone sulfate, SHBG, and bioestrogen compared with transdermal estradiol, even when both delivered the same parent molecule. The liver’s processing of oral estradiol shifts the hormonal milieu in ways that going through the skin does not.
For most women, these liver effects are manageable and clinically acceptable. But for women who have conditions affected by SHBG levels, clotting factors, or thyroid-binding proteins, transdermal delivery can sidestep complications that oral delivery might create. This is a conversation worth having with a prescriber, and it has nothing to do with whether the estrogen came from a horse.
The Animal Welfare Dimension
A separate thread in the horse-urine conversation involves the welfare of the mares used in Premarin production. Pregnant mares on PMU (pregnant mare urine) farms are fitted with urine collection devices and kept in stalls for much of their pregnancy so that their urine can be collected. Animal advocacy groups have raised concerns about confinement conditions, the fate of the foals born as byproducts of the process, and the overall ethics of using animal-derived pharmaceuticals when synthetic alternatives exist.
Research into the welfare of mares fitted with urine collection devices has been conducted, though the evidence base is limited and the conclusions depend heavily on the specific farming practices studied. The existence of plant-derived, fully synthetic estradiol as a therapeutic alternative has given animal welfare advocates a concrete argument: if the clinical goal can be achieved with a molecule that does not require horses at all, the ethical case for continuing to use CEE weakens. This argument resonates with many patients and has likely contributed to the gradual market shift away from Premarin toward estradiol-based products over the past two decades, though clinical considerations around efficacy and safety data from the Women’s Health Initiative also played a major role in that shift.
Estrogens as Environmental Contaminants
Whether estrogens come from horses, from human bodies, or from pharmaceutical manufacturing, they all end up in the environment to some degree. A systematic review cataloging estrogens detected in water resources across 59 countries identified 39 different estrogen compounds, both natural and synthetic, at concentrations ranging from trace amounts to extremely high levels. The most frequently detected were estrone, estradiol, and ethinylestradiol (the synthetic estrogen in most birth control pills). These compounds were found in wastewater treatment plant effluents, rivers, lakes, surface waters, and even drinking water sources.
The environmental question does not distinguish horse-derived from plant-derived estradiol, because once 17β-estradiol is in your body and subsequently excreted, it is the same molecule regardless of its origin. The environmental footprint of Premarin production does add an extra dimension, since horse farming generates agricultural runoff that may carry its own estrogen load. But in the bigger picture, the dominant sources of estrogenic contamination in waterways are human sewage and agricultural runoff from livestock operations of all kinds, not specifically PMU farms. If environmental impact is your concern, the manufacturing origin of your estrogen prescription is a small piece of a much larger puzzle involving wastewater treatment infrastructure and agricultural practices worldwide.
Equine Estrogens in Human Biology
One underappreciated aspect of taking CEE is that the equine estrogens it contains are not quickly eliminated. Some of these ring B unsaturated compounds, particularly equilin sulfate, have long half-lives and can be detected in the body for extended periods after a dose. Because human bodies did not evolve to process these particular molecules, their metabolic fate is somewhat unpredictable compared with endogenous estradiol, which the body breaks down through well-characterized enzymatic pathways.
The receptor research described earlier also raises intriguing possibilities. Because certain equine estrogens preferentially activate ERβ, and because ERβ has been associated with potentially protective effects in some tissues, there has been interest in whether specific ring B unsaturated estrogens could be developed as selective therapeutic agents for conditions where ERβ activation is desirable. Researchers have suggested it may be possible to develop hormone therapy using selective ring B unsaturated estrogens targeted to tissues where ERβ predominates. That work remains largely experimental, but it reframes the equine estrogens not simply as contaminants in an impure product but as molecules with distinct pharmacological properties that might eventually find targeted uses.
None of this changes the basic answer to the title question. Estradiol, the specific molecule, is synthesized in a lab from plant precursors and has never been collected from horses. The horse-derived product is something else entirely, with a different name, a different composition, and meaningfully different biological behavior.